Not Signed In - Endo Receives FDA Approval For Opana(R) ER (oxymorphone HCl) Extended-Release And Opana(R) (oxymorphone HCl) Immediate Release Tablets CII
Sat, 24 Jun 2006 06:00 AM EST
... Endo Pharmaceuticals Inc., awholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq:ENDP), today announced that the U.S. Food and Drug Administration (FDA) hasgranted final approval of the company's New Drug Applications (NDAs) forits extended- release and immediate-release formulations of oxymorphonehydrochloride. [click link for full article] ...
Related Topics
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Niacin Extended Release
- Metronidazole Extended Release
- Valproic Acid Delayed or Extended-Release or Sprinkle Capsule
- Metformin Extended-Release
- Lovastatin Extended Release
- Diltiazem
- Isosorbide Dinitrate, Tablets or Extended-Release Tablets or Capsules
- Methylphenidate ER
- Isradipine Extended-Release Tablets
- Pseudoephedrine Extended Release
- Bupropion Extended-Release
- Chlorpromazine Extended-Release Capsules
- Tizanidine
- Erythromycin Tablets, Capsules, and Extended-Release
- Quinidine Extended-Release
- Glipizide Extended-Release
- Aspirin and Extended-Release Dipyridamole
- Niacin extended-release and lovastatin
- Loratadine and Pseudoephedrine
email this page
print this page
bookmark this page
feedback on this page
